IPSEN (OTCMKTS:IPSEY) Shares Up 7.1% – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares shot up 7.1% on Friday. The company traded as high as $43.85 and last traded at $43.85. Approximately 1,175 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 1,991 shares. The stock had previously closed at $40.93.

Wall Street Analysts Forecast Growth

IPSEY has been the subject of several research analyst reports. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Barclays upgraded shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

IPSEN Trading Up 2.0%

The stock’s fifty day moving average is $44.36 and its two-hundred day moving average is $46.01.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.